Sugi Predict

Sugi Predict / Compounds / SCHEMBL10158896

SCHEMBL10158896

SCHEMBL10158896

CC(C)OC(=O)N(C)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.43
▸ LMNA P02545 3/20 0.36
▸ HTT P42858 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.34
▸ CA12 O43570 5/20 0.31
▸ CA1 P00915 5/20 0.31
▸ CA2 P00918 5/20 0.31
▸ CA9 Q16790 5/20 0.31
▸ CA14 Q9ULX7 5/20 0.31
▸ CA7 P43166 4/20 0.31
▸ AKR1B10 O60218 1/20 0.31
▸ AKR1B1 P15121 1/20 0.31
▸ CHRNB2 P17787 1/20 0.30
▸ CHRNA4 P43681 1/20 0.30
▸ ADRA1A P35348 1/20 0.30
▸ PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18924870 0.80 — —
SCHEMBL22267759 0.80 — —
SCHEMBL25657139 0.80 TSHR (0.40) TSHRLMNAHTTNPSR1HCAR2
SCHEMBL6244866 0.78 — —
SCHEMBL25692130 0.77 ALOX5 (0.45) TSHRLMNAHTTNPSR1HCAR2
SCHEMBL8386794 0.77 TSHR (0.37) TSHRLMNAHTTNPSR1HCAR2
SCHEMBL8386796 0.77 TSHR (0.37) TSHRLMNAHTTNPSR1HCAR2
SCHEMBL12988855 0.76 TSHR (0.46) TSHRLMNAHTTNPSR1HCAR2
SCHEMBL3636117 0.76 — —
SCHEMBL8593195 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104530417-B A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof 厦门赛诺邦格生物科技股份有限公司 2017-09-08 — — CN claimed
CN-104530415-B A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance 厦门赛诺邦格生物科技股份有限公司 2017-09-01 — — CN claimed
CN-114736219-B Antitumor compounds 法马马有限公司 2024-06-07 — — CN disclosed
CN-114751920-B Antitumor compounds 法马马有限公司 2024-06-07 — — CN disclosed
CN-117865987-A Antitumor compounds 法马马有限公司 2024-04-12 — — CN disclosed
US-20230374035-A1 RAS INHIBITORS Revolution Medicines, Inc. 2023-11-23 — — US disclosed
US-20230374035-A1 RAS INHIBITORS Revolution Medicines, Inc. 2023-11-23 — — US disclosed
US-11771715-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-03 — — US disclosed
US-11766449-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-09-26 — — US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring CAPULUS THERAPEUTICS, LLC (US) 2023-08-08 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2009-06-25 — — US disclosed
US-20080015179-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 — — US disclosed
CN-1882524-A 4- ((phenoxyalkyl) thio) -phenoxyacetic acids and analogs JANSSEN PHARMACEUTICA NV (BE) 2006-12-20 — — CN disclosed
CN-1127502-C Paroxetine methanesulfonate SMITHKLINE BEECHAM PLC (GB) 2003-11-12 — — CN disclosed
CN-1077439-C Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions GEN HOSPITAL CORP (US) 2002-01-09 — — CN disclosed
CN-1315949-A Salts of paroxetine SMITHKLINE BEECHAM PLC (GB) 2001-10-03 — — CN disclosed
CN-1141002-A Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions GEN HOSPITAL CORP (US) 1997-01-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring SREBF1, SREBF2, XBP1 TSHR 1549/4885LMNA 499/4885HTT 4287/4885
US-11771715-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB TSHR 1491/4885LMNA 918/4885HTT 1965/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 TSHR 1768/4885LMNA 4438/4885HTT 854/4885
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS IL17A, IL23R, IL2 TSHR 3663/4885LMNA 3835/4885HTT 3216/4885
US-20080015179-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 TSHR 131/4885LMNA 4093/4885HTT 3195/4885
US-20230374035-A1 RAS INHIBITORS KRAS, NRAS, HRAS TSHR 3332/4885LMNA 3803/4885HTT 2559/4885
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders REL, NFATC1, BCL6 TSHR 965/4885LMNA 3579/4885HTT 4184/4885
US-11766449-B2 Circular RNA compositions and methods RTCB, RNGTT, HNRNPAB TSHR 1390/4885LMNA 1053/4885HTT 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.